Oneview Healthcare (ONE) investor relations material

Executive summary

• Recurring revenue grew 13% year-over-year to €4.3 million, now representing 79% of total revenue, while total revenue declined 14% to €5.5 million due to lower non-recurring contributions.

• Gross margin increased nine points to 70% (up from 61%), maintaining gross profit at €3.8 million despite lower revenue.

• Operating EBITDA loss improved by 11% year-over-year to €4.0 million, reflecting cost discipline and restructuring.

• Cash position at June 30 was €7.2 million, with a pro forma balance of €11.4 million after a A$19 million placement.

• Strategic initiatives included the launch of Bedside Hub, Epic certification, and inclusion in a major US health system's procurement framework.

Financial highlights

• Recurring revenue up 13% year-over-year; non-recurring revenue down 54%.

• Gross margin improved to 70% (up from 61% year-over-year).

• Cash operating expenses reduced by 6% to €7.8 million, mainly from lower employee costs.

• Operating cash outflow decreased 15% year-over-year to €4.1 million.

• Net assets increased 73% since December 2025, driven by capital raise.

Outlook and guidance

• Management is focused on reaching cash flow breakeven, leveraging recurring revenue growth and cost efficiencies.

• Bedside Hub is expected to accelerate sales cycles and provide a lighter-touch deployment, targeting cost-conscious segments.

• Pipeline includes 16 Bedside Hub opportunities representing over 20,000 beds, with pilots underway at major US health systems.

• Targeting 3-4 new Bedside Hub logo wins and continued ARR growth.

• First deployments of the new front end and Ovie pilots scheduled for H2 2026.